For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Attruby represents a true advancement . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and reducing the severity of the illness. Patients are now seeing positiv… Read More